18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

Description

The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.

Conditions

Congenital Hyperinsulinism

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.

18F-Fluoro-L- DOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

Condition
Congenital Hyperinsulinism
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Any age, but primarily infants 0-6 months given typical age of initial presentation.
  • * Children with diagnosis of FoHI or DiHI based on clinical criteria (fasting hypoglycemia accompanied by inadequate suppression of plasma insulin, inappropriately low plasma free fatty acid and plasma-hydroxybutyrate concentrations, and an inappropriate glycemic response to glucagon injection)
  • * Hypoglycemia uncontrolled with medical management (diazoxide, octreotide).
  • * Able to withdraw medications in time to wash out prior to the scheduled PET scan.
  • * Patients fulfilling criteria above but with uncontrolled hypoglycemia after initial surgical management (partial or near-total pancreatectomy)
  • * Normal hepatic and renal function.
  • * Treatment with other, third-line, medications for hyperinsulinism (nifedipine, glucagon).
  • * Patients with hepatic or renal insufficiency.

Ages Eligible for Study

0 Days to 18 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Miguel Pampaloni,

Miguel Hernandez Pampaloni, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2026-12-31